Conference
Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.
Authors
Hotte SJ; Yu EY; Hirte HW; Higano CS; Gleave ME; Chi KN
Volume
28
Pagination
pp. 3077-3077
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2010
DOI
10.1200/jco.2010.28.15_suppl.3077
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X